The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Toxicities associated with ide-cel in KarMMa
Doris K. Hansen, MD, Moffitt Cancer Center, Tampa, FL, reflects on toxicities associated with idecabtagene vicleucel (ide-cel) in multiple myeloma including neurotoxicity, cytokine release syndrome (CRS) and cytopenias. Dr Hansen highlights strategies employed to mitigate the incidence of treatment-related adverse events. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
